Ridaforolimus

Type: Product
Name: Ridaforolimus
First reported Oct 13 2014 - Updated Oct 13 2014 - 1 reports

EMA safety panel rules no change needed for Ariad's Iclusig

The European Medicines Agency (EMA) has ruled the continued use of Ariad's cancer therapy Iclusig unchanged in the EU.The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) brought an investigation into the safety of Iclusig (ponatinib) to a close ... [Published PMLive - Oct 13 2014]
First reported May 13 2014 - Updated May 13 2014 - 1 reports

IMPAKT Combination of mTOR and AKT inhibitors in patients with advanced breast cancer

A combination of mTOR inhibitor, ridaforolimus and novel AKT inhibitor, MK-2206, showed activity in heavily pretreated hormone positive and negative breast cancer patients who exhibit PI3K pathway dependence, based on low RAS signature score. The...Related ... [Published BioPortfolio - May 13 2014]

Quotes

Ariad's chief executive Harvey Berger commented: "The PRAC recommendation provides insightful guidance to healthcare professionals and patients regarding the use of Iclusig … and importantly, leaves the original Iclusig indication statement unchanged.”"
NEXT ARTICLE More From BioPortfolio on "IMPAKT: Combination of mTOR and AKT inhibitors in patients with advanced breast cancer"

More Content

All (2) | News (2) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
EMA safety panel rules no change needed for Ari... [Published PMLive - Oct 13 2014]
IMPAKT Combination of mTOR and AKT inhibitors i... [Published BioPortfolio - May 13 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.